All In Biotech

Drug Trial Radar · NCT03938792

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

188

Actual

Start

Mar 9, 2020

Primary completion

Apr 29, 2025

Study completion Apr 29, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of inhibitors. The potential for once weekly (QW) subcutaneous (SC) administration provides for treatment options in the absence of reliable vascular access, increased convenience and may enable better compliance. Combined, these qualities should result in a reduction of bleeding episodes.

Conditions

  • Hemophilia A
  • Hemophilia B

Interventions

  • PF-06741086Drug

    300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP)Time frame: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
  2. Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With Prior OD Therapy at OP)Time frame: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
  3. Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With RP at OP)Time frame: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
  4. Number of Participants With Adverse Events (AEs): Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
  5. Number of Participants With Serious Adverse Events (SAEs): Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
  6. Number of Participants With Thrombotic Events: Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
  7. Number of Participants With Thrombotic Microangiopathy: Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
  8. Number of Participants With Disseminated Intravascular Coagulation/ Consumption Coagulopathy: Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
  9. Number of Participants With Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF- 06741086: Inhibitor and Non-Inhibitor CohortTime frame: During prophylaxis treatment in ATP (12 months)
  10. Number of Participants With Transient and Persistent ADA and NAb Against PF-06741086: Inhibitor and Non-Inhibitor CohortTime frame: During prophylaxis treatment in ATP (12 months)
  11. Number of Participants With Injection Site Reactions (ISRs): Inhibitor and Non-Inhibitor CohortTime frame: During prophylaxis treatment in ATP (12 months)
  12. Number of Participants With Clinically Significant Changes in Physical Examinations: Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
  13. Number of Participants With Clinically Significant Changes in Vital Signs: Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
  14. Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters: Inhibitor and Non-Inhibitor CohortTime frame: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
  15. Number of Participants With Severe/ Systematic Hypersensitivity and Anaphylactic Reactions: Inhibitor and Non-Inhibitor CohortTime frame: During prophylaxis treatment in ATP (12 months)

Locations

62 sites in 20 countries. Site status is shown where the registry gives one.

  • USF Health Morsani Center For Advanced Healthcare

    Tampa, Florida

  • University of Iowa

    Iowa City, Iowa

  • Northwell Health HTC

    New Hyde Park, New York

  • Washington Institute for Coagulation

    Seattle, Washington

  • National Specialized Hospital for the Active Treatment of Hematological Diseases - EAD, Sofia

    Sofia, Bulgaria

  • UMHAT "Prof.Dr. Stoyan Kirkovich"

    Stara Zagora, Bulgaria

  • McMaster University Medical Centre - Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • McMaster Children's Hospital

    Hamilton, Ontario, Canada

  • McMaster University

    Hamilton, Ontario, Canada

  • The Hospital For Sick Children

    Toronto, Ontario, Canada

  • Beijing Children's Hospital, Capital Medical University

    Beijing, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China

  • Institute of Hematology, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • Klinicki bolnicki centar Zagreb

    Zagreb, Croatia

  • Hôpital Necker Enfants Malades

    Paris, France

  • Prince of Wales Hospital

    Hong Kong, Hong Kong

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Nirmal Hospital Pvt, Ltd

    Surat, Gujarat, India

  • Sahyadri Clinical Research and Development Center

    Pune, Maharashtra, India

  • Sahyadri Super Speciality Hospital

    Pune, Maharashtra, India

  • Christian Medical College

    Vellore, Tamil Nadu, India

  • Università degli Studi di Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria della

    Perugia, Italy

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Milan, Italy

  • Università degli Studi di Roma "Sapienza"-Policlinico Umberto I

    Roma, RM, Italy

  • Hiroshima University Hospital

    Hiroshima, Japan

  • Nagoya University Hospital - Transfusion Medicine

    Nagoya, Aichi-ken, Japan

  • Sapporo Tokushukai Hospital

    Sapporo, Hokkaido, Japan

  • Saitama Medical University Hospital

    Iruma-gun, Saitama, Japan

  • Hospital Universitario "Dr Jose Eleuterio Gonzalez"

    Monterrey, Nuevo León, Mexico

  • Centro Multidisciplinario para el Desarrollo Especializado de la Inv. Clínica en Yucatán, S.C.P.

    Mérida, Yucatán, Mexico

  • Sultan Qaboos University Hospital

    Muscat, Oman

  • FGBOU VO "Samara State Medical University" of MoH of Russia

    Samara, Russia

  • King Abdulaziz University Hospital

    Jeddah, Saudi Arabia

  • King Faisal Specialist Hospital & Research Center

    Riyadh, Saudi Arabia

  • Clinical Center of Serbia

    Belgrade, Serbia

  • Institute for Mother and Child healthcare "Dr Vukan Cupic"

    Belgrade, Serbia

  • Clinical Center Kragujevac

    Kragujevac, Serbia

  • Clinical Center Nis

    Niš, Serbia

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.